You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
3 months and 1 year of oral anticoagulant treatment were equivalent for idiopathic proximal deep venous thrombosis

https://doi.org/10.1136/ebm.7.1.17

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) N Engl J Med 345, 165. Agnelli G, Prandoni P, Santamaria MG. , et al, and the Warfarin Optimal Duration Italian Trial Investigators. . Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis.. Jul 19;. :. –9.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients who have had a first episode of idiopathic proximal deep venous thrombosis, what is the long term effectiveness of extending to 1 year the initial 3 month course of oral anticoagulant treatment?

    Design

    Randomised (unclear allocation concealment*), unblinded,* controlled trial with ≥ 2 years of follow up.

    Setting

    10 study centres in Italy.

    Patients

    267 patients (mean age 67 y, 58% men) who had a first episode of symptomatic idiopathic proximal deep venous thrombosis confirmed by compression ultrasonography or venography, and had completed 3 uninterrupted months of oral anticoagulant treatment without a recurrence of thromboembolism or bleeding. Exclusion criteria included anticoagulant treatment for reasons other than venous thromboembolism, major psychiatric disorders, life expectancy < 2 years, and inability to return for follow up. 90% of patients completed the study.

    Intervention

    After 3 months of treatment with warfarin (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant treatment for 9 additional months. The dose of the oral anticoagulant was adjusted to maintain an international normalised ratio of 2.0 to 3.0.

    Main outcome measures

    The …

    View Full Text